BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Indevus Pharmaceuticals, Inc. (Formerly Interneuron Pharmaceuticals Inc.) 

Corporate Headquarters
33 Hayden Avenue
Lexington  Massachusetts  02421  U.S.A.
Phone: 781-861-8444 Fax: 781-861-3830


SEARCH JOBS

Indevus Pharmaceuticals is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. Our approved products include SANCTURA® and SANCTURA® XR for overactive bladder, which we co-promote with our partner Allergan, Inc., VANTAS® for advanced prostate cancer, SUPPRELIN® LA for central precocious puberty, and DELATESTRYL® for the treatment of hypogonadism. We market our products through an approximately 100-person specialty sales force.

Our core urology and endocrinology portfolio contains multiple compounds in development in addition to our approved products. Our most advanced compounds are NEBIDO® for male hypogonadism, VALSTAR™ for bladder cancer, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted diseases, the octreotide implant for acromegaly and a biodegradable ureteral stent used in association with the treatment of kidney stones.

In addition to our core urology and endocrinology portfolio, there are multiple compounds outside of our core focus area which we either currently outlicense for development and commercialization, or intend to outlicense in the future. These compounds include pagoclone for stuttering, ALKS 27 for chronic obstructive pulmonary disease which we have been jointly developing with Alkermes, Inc., aminocandin for systemic fungal infections for which we licensed the know-how to Novexel S.A. and IP 751 for pain and inflammation for which we recently licensed worldwide rights to Cervelo Pharmaceuticals, Inc.

 Key Statistics


Email:
Ownership: Public

Web Site: Indevus Pharmaceuticals, Inc.
Employees:
Symbol: IDEV
 









 Company News
Endo Pharmaceuticals (ENDP) Completes Acquisition of Indevus Pharmaceuticals, Inc. (IDEV) 3/24/2009 8:07:44 AM    More...
Endo Pharmaceuticals (ENDP) Announces Successful Completion of Tender Offer for Indevus Pharmaceuticals, Inc. (IDEV) 3/19/2009 11:03:32 AM    More...
Indevus Pharmaceuticals, Inc. (IDEV)'s Valstar Reintroduced into Bladder Cancer Market 3/3/2009 8:14:05 AM    More...
Endo Pharmaceuticals (ENDP) Announces Extension of its Tender Offer for Shares of Indevus Pharmaceuticals, Inc. (IDEV) 3/2/2009 12:00:54 PM    More...
Endo Pharmaceuticals (ENDP) Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals, Inc. (IDEV) and Announces Subsequent Offering Period 2/23/2009 11:06:19 AM    More...
Indevus Pharmaceuticals, Inc. (IDEV) Announces AIDS Gel, PRO 2000 Found to Show Promise in Large HIV Prevention Study 2/9/2009 9:03:18 AM    More...
Indevus Pharmaceuticals, Inc. (IDEV) Announces First Quarter Fiscal 2009 Financial Results 2/5/2009 11:39:39 AM    More...
Endo Pharmaceuticals (ENDP) To Buy Indevus Pharmaceuticals, Inc. (IDEV) in $637 Million Deal 1/5/2009 2:39:43 PM    More...
Indevus Pharmaceuticals, Inc. (IDEV) Announces Fiscal 2008 Year End and Fourth Quarter Results 11/26/2008 9:39:42 AM    More...
Indevus Pharmaceuticals, Inc. (IDEV) to Announce Fiscal 2008 Financial Results on Tuesday, November 25, 2008 Company to Conduct Conference Call and Webcast 11/18/2008 10:38:43 AM    More...
12345678910...

//-->